SCHEMBL4855010

SCHEMBL4855010

CCOC(=O)c1nc2ccoc2nc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 6/20 0.42
PDCD4 Q53EL6 1/20 0.42
GLP1R P43220 1/20 0.40
ALDH1A1 P00352 4/20 0.39
HPGD P15428 3/20 0.39
POLB P06746 2/20 0.39
MAPK1 P28482 2/20 0.39
HTT P42858 2/20 0.39
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
CYP1A2 P05177 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.36
HSD17B10 Q99714 2/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
XBP1 P17861 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4857813 0.83 GLP1R (0.42) TARBP2PDCD4GLP1RALDH1A1HPGD
SCHEMBL4861845 0.83 GLP1R (0.36) TARBP2GLP1RALDH1A1HTTCYP1A2
SCHEMBL4849652 0.83 POLB (0.39) ALDH1A1HPGDPOLBCYP1A2L3MBTL1
SCHEMBL4862703 0.80 GLP1R (0.42) TARBP2PDCD4GLP1RALDH1A1HPGD
SCHEMBL2023364 0.79 L3MBTL1 (0.49) TARBP2ALDH1A1HPGDPOLBMAPK1
SCHEMBL4854555 0.76 ALDH1A1 (0.36) ALDH1A1HPGDCYP1A2KDM4EGAA
SCHEMBL6207970 0.71 L3MBTL1 (0.35) ALDH1A1HPGDPOLBCYP1A2L3MBTL1
SCHEMBL10402795 0.71 TSHR (0.45) TARBP2GLP1RALDH1A1HPGDKDM4E
SCHEMBL16011579 0.70 ALDH1A1 (0.43) TARBP2PDCD4ALDH1A1HPGDPOLB
SCHEMBL4857338 0.70 NPSR1 (0.41) ALDH1A1HPGDKDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456192-B2 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof PIERRE FABRE MEDICAMENT (FR) 2008-11-25 US disclosed
EP-1440075-B1 NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF PF MEDICAMENT (FR) 2005-06-08 EP disclosed
US-20050080085-A1 Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof PIERRE FABRE MEDICAMENT (FR) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080085-A1 Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof AOC3, MAOB, AOC1 TARBP2 4056/4885PDCD4 1456/4885GLP1R 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.